The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

A. D'Addio, A. Curti, N. Worel, K. Douglas, M. R. Motta, S. Rizzi, E. Dan, S. Taioli, V. Giudice, H. Agis, G. Kopetzky, R. Soutar, B. Casadei, M. Baccarani, R. M. Lemoli

Research output: Contribution to journalArticlepeer-review

Abstract

We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.

Original languageEnglish
Pages (from-to)356-363
Number of pages8
JournalBone Marrow Transplantation
Volume46
Issue number3
DOIs
Publication statusPublished - Mar 2011

Keywords

  • autologous stem cell transplantation
  • PBSC mobilization
  • plerixafor
  • poor mobilizers

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF'. Together they form a unique fingerprint.

Cite this